Deckers Brands has raised its full-year revenue growth outlook by 15% after delivering record quarterly revenue in Q3 of 2025 ...

BofA analyst Jason Gerberry lowered the firm’s price target on Teva (TEVA) to $23 from $26 and keeps a Buy rating on the shares. For FY25, the ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Deckers Brands (DECK) stock dropped Friday afternoon despite a third quarter revenue beat, as Wall Street was disappointed by ...

UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for ...

Teva Pharma Industries Ltd ADR, Allergan PLC, Johnson & Johnson, CVS Health Corp. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

Shares of Deckers Outdoor were down nearly 20% Friday afternoon, one day after the footwear maker released its quarterly results.